News
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.
Danish leader will face a challenging landscape among competitors ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down Updated on: May 16, 2025 / 10:09 AM EDT / AP People using weight loss drugs like Ozempic and Wegovy drink less ...
A version of this article appears in print on May 17, 2025, Section B, Page 5 of the New York edition with the headline: Novo Nordisk, Its Stock Falling and Competition Rising, Will Replace Its C ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback